2026 Q3 Portfolio Activity
In 2026 Q3, Avoro Capital Advisors LLC maintained a portfolio of 31 distinct positions. The most significant new addition was DAMORA THERAPEUTICS INC, now representing 0.83% of the total fund value. The fund also reduced its exposure to CELCUITY INC by 55.9%.
Position History
hover any row below to update
Loading…
Total Positions
31
Quarter
2026 Q3
Top Holding
UTHR (15.4%)
Top 10 Concentration
83.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-31 of 31
Avoro Capital Advisors LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
UTHR
UNITED THERAPEU...
|
Healthcare | 15.41% | 13.52% |
#1
Prev: #1
|
6.5 |
—
|
-22,222 | -0.8% |
P
S
|
2,755,555 | $1,493,207,699 | 2020 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 11.87% | 12.24% |
#2
Prev: #2
|
6.0 |
—
|
-61,111 | -1.2% |
P
S
|
5,050,000 | $1,150,541,500 | 2016 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 9.91% | 9.64% |
#3
Prev: #3
|
6.0 |
—
|
no change | no change |
P
S
|
2,888,888 | $960,728,593 | 2021 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ARGX
ARGENX SE
|
Healthcare | 9.89% | 8.33% |
#4
1
Prev: #5
|
5.5 |
—
|
no change | no change |
P
S
|
1,000,000 | $958,910,000 | 2017 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 9.53% | 8.84% |
#5
1
Prev: #4
|
5.3 |
—
|
no change | no change |
P
S
|
1,833,333 | $923,926,499 | 2018 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 8.62% | 7.70% |
#6
1
Prev: #7
|
4.4 |
—
|
no change | no change |
P
S
|
7,474,747 | $835,601,967 | 2020 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ARWR
ARROWHEAD PHARM...
|
Healthcare | 7.43% | 8.31% |
#7
1
Prev: #6
|
3.5 |
—
|
-355,555 | -3.1% |
P
S
|
11,000,000 | $719,950,000 | 2014 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 4.54% | 3.86% |
#8
Prev: #8
|
2.3 |
—
|
-152,000 | -6.6% |
P
S
|
2,145,000 | $440,282,700 | 2020 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 3.33% | 3.82% |
#9
Prev: #9
|
1.8 |
—
|
-99,999 | -2.0% |
P
S
|
4,900,000 | $322,959,000 | 2016 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 2.77% | 3.04% |
#10
3
Prev: #13
|
1.6 |
—
|
-138,888 | -1.9% |
P
S
|
7,050,000 | $268,323,000 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 2.12% | 3.16% |
#11
Prev: #11
|
1.8 |
—
|
no change | no change |
P
S
|
6,555,555 | $204,992,205 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.11% | 3.13% |
#12
Prev: #12
|
1.3 |
—
|
-277,777 | -4.8% |
P
S
|
5,500,000 | $204,545,000 | 2018 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 1.88% | 2.21% |
#13
2
Prev: #15
|
1.3 |
—
|
-88,888 | -1.6% |
P
S
|
5,635,000 | $181,954,150 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
QURE
UNIQURE NV
|
Healthcare | 1.68% | 2.78% |
#14
Prev: #14
|
1.7 |
—
|
no change | no change |
P
S
|
6,727,777 | $162,543,092 | 2015 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CELC
CELCUITY INC
|
Healthcare | 1.23% | 3.19% |
#15
5
Prev: #10
|
0.5 |
—
|
-1,900,000 | -55.9% |
P
S
|
1,500,000 | $119,280,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 1.20% | 1.46% |
#16
Prev: #16
|
1.5 |
—
|
no change | no change |
P
S
|
23,888,888 | $116,338,885 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 0.98% | 1.11% |
#17
Prev: #17
|
0.9 |
—
|
-159,700 | -1.3% |
P
S
|
12,380,300 | $94,956,901 | 2024 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
DAMORA THERAPEU...
|
|
Unknown | 0.83% | — |
#18
Prev: #—
|
3.8 |
—
|
3,783,000 | — |
NEW
|
3,783,000 | $80,502,240 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
COAG
HEMAB THERAPEUT...
|
Healthcare | 0.60% | 0.63% |
#19
Prev: #19
|
0.7 |
—
|
-32,778 | -1.7% |
P
S
|
1,892,372 | $58,360,752 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.53% | 0.41% |
#20
1
Prev: #21
|
1.2 |
—
|
no change | no change |
P
S
|
2,500,000 | $51,475,000 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SEPN
SEPTERNA INC
|
Healthcare | 0.52% | 0.40% |
#21
1
Prev: #22
|
0.7 |
—
|
-37,500 | -2.8% |
P
S
|
1,300,000 | $50,869,000 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 0.50% | — |
#22
Prev: #—
|
3.7 |
—
|
488,000 | — |
NEW
|
488,000 | $48,321,760 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SCTX
SCRIBE THERAPEU...
|
Healthcare | 0.49% | — |
#23
Prev: #—
|
3.7 |
—
|
2,598,973 | — |
NEW
|
2,598,973 | $47,834,098 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 0.43% | 0.32% |
#24
Prev: #24
|
0.7 |
—
|
-34,039 | -2.4% |
P
S
|
1,410,000 | $41,933,400 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GHRS
GH RESEARCH PLC
|
Healthcare | 0.43% | 0.43% |
#25
5
Prev: #20
|
0.7 |
—
|
-30,000 | -1.7% |
P
S
|
1,770,000 | $41,559,600 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
BIOHAVEN LTD
|
|
Unknown | 0.38% | — |
#26
Prev: #—
|
3.7 |
—
|
2,750,000 | — |
NEW
|
2,750,000 | $36,712,500 | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.38% | 0.39% |
#27
4
Prev: #23
|
0.7 |
—
|
44,444 | 1.9% |
P
S
|
2,377,777 | $36,451,321 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BRVE
BRAVEHEART BIO ...
|
Healthcare | 0.26% | — |
#28
Prev: #—
|
3.6 |
—
|
1,255,000 | — |
NEW
|
1,255,000 | $25,351,000 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
WHWK
WHITEHAWK THERA...
|
Healthcare | 0.11% | 0.12% |
#29
4
Prev: #25
|
1.0 |
—
|
no change | no change |
P
S
|
2,849,402 | $10,713,752 | 2021 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.02% | 0.06% |
#30
4
Prev: #26
|
0.0 |
—
|
-964,189 | -64.7% |
P
S
|
525,000 | $1,774,500 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GLTO
DAMORA THERAPEU...
|
Healthcare | 0.00% | 0.88% |
Sold All 😨
(Was: #18) |
0.0 |
—
|
-3,783,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-31 of 31 holdings